Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P830055/S374

LCS(R) TOTAL KNEE SYSTEM, specifically ATTUNE Cruciate Retaining (CR), Posterior Stabilized (PS) and Revision Femoral C

Depuy, Inc. · Decision date Sep 3, 2026

MEDTECHLEDGER EXPLANATIONP830055/S374

What did the FDA decide?

The FDA record lists decision OK30 dated 2026-09-03 for supplement S374 to P830055, filed as a 30-Day Notice for a process change involving manufacturer, sterilizer, packager or supplier. The stated change is the addition of the DePuy Ireland, Cork facility as an alternative site for Hot Isostatic Pressing and heat treatment of Attune Cruciate Retaining, Posterior Stabilized and Revision Femoral Components cast at the Raynham Foundry.

The identifier ties the notice to the existing LCS Total Knee System PMA file, but the record does not approve the system anew or establish that the listed components are the whole device. It also does not show whether the Cork processing was compared with Raynham output, what validation data were reviewed, or any clinical finding; the statement gives no evidence of safety or effectiveness beyond the reported purpose.

Volume and component scope of production at Cork are absent, as are the HIP and heat-treatment parameters; the notice does not specify which of the three component types will use the Cork site.

FDA approval order statement

addition of the DePuy Ireland, Cork facility as an alternative facility for the Hot Isostatic Pressing (HIP) and Heat treatment processing of ATTUNE(TM) Cruciate Retaining (CR), Posterior Stabilized (PS) and Revision Femoral Components casted by the Raynham Foundry
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Orthopedic
Decision date
Sep 3, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P830055/S374
Regulatory pathway
PMA supplement
Applicant
Depuy, Inc.
Product code
NJL
Decision code
OK30
Decision date
Sep 3, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Prosthesis, knee, patellofemorotibial, semi-constrained, metal/polymer, mobile bearing.

Applicant
Depuy, Inc.
Product code
NJL
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P830055/S374 received

    Application receipt date recorded by FDA.

  2. P830055/S374 · FDA decision

    30-Day Notice

  3. P830055/S372 · Related supplement

    ATTUNE Rotating Platform (RP) Total Knee System, ATTUNE Cementless Rotating Platform (RP) Knee System, ATTUNE Revision R

  4. P830055/S376 · Related supplement

    Attune Rotating Platform (RP) Total Knee System and the DePuy P.F.C. Sigma Rotating Platform (RP) Total Knee System an

  5. P830055/S351 · Related supplement

    Attune Revision Knee System

  6. P830055/S377 · Related supplement

    ATTUNE Rotating Platform (RP) Total Knee System, ATTUNE Revision Rotating Platform (RP) Total Knee System, and M.B.T. Re

  7. P830055/S379 · Related supplement

    ATTUNE Revision Knee System

  8. P830055/S381 · Related supplement

    ATTUNE Rotating Platform (RP) Total Knee System, and ATTUNE Revision Rotating Platform (RP) Knee System

Timeline entries are records held by MedtechLedger for P830055. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P830055

Explore the linked device profile

Other records with product code NJL

Product / regulatory recordCompanyPathwayDecision dateSource
Zimmer, Inc.PMA supplementOct 16, 2026FDA
Zimmer, Inc.PMA supplementSep 24, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Depuy, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
P.O. Box 988, 700 Orthopaedic Dr., Warsaw, IN, 46581

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records